Skip to main navigation

About

Our Story Executive Team Board of Directors

Technology and Platforms

Our Approach FasTCAR TruUCAR Manufacturing

Pipeline

Investors

Overview News & Events Financial Information Stock Information Corporate Governance IR Resources Contact Us

Media Coverage

Overview
News & Events
Financial Information
Stock Information
Corporate Governance
IR Resources
Contact Us

News & Events menu

Press Releases
Events & Presentations
In the News
Scientific Publications

Year

Gracell gives sneak peek into leukemia CAR-T cell program ahead of EHA

May 12, 2023

Source

Endpoints News

Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

Jan 09, 2023

Source

PharmaVoice

Gracell's CAR-T wows, Takeda puts down $4B on Nimbus' TYK2 inhibitor, Bio Farma strikes Merck deal

Dec 16, 2022

Source

Fierce Pharma Asia

ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

Dec 12, 2022

Source

Fierce Biotech

Gracell Biotechnologies doses first patient in Phase 2 portion of registrational Phase 1/2 clinical trial evaluating treatment of B-cell acute lymphoblastic leukemia

Oct 20, 2022

Source

Drug Development & Delivery

Gracell continues progress in r/r B-Cell acute lymphoblastic leukemia

Oct 17, 2022

Source

CGT Live

Gracell Biotechnologies doses first patients in First-in-Human clinical trial evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin’s lymphoma

Feb 21, 2022

Source

Pharmtech Focus

Gracell doses first patients in First-in-Human clinical trial of dual-targeting CAR-T therapy

Feb 17, 2022

Source

Drug Development & Delivery

Gracell Biotechnologies begins treating B-NHL patients with CAR T-Cell therapy in trial

Feb 17, 2022

Source

Precision Oncology News

Shareholder Tools

Contact Us
Email Alerts
FAQs
RSS Feeds

Footer Links

Terms & Conditions
Privacy Policy
Contact Us
Careers

© 2023 Gracell All Rights Reserved.